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Leo Anerlrs, Celif rnia
Recent studies of laterventional therapy by way of the coronary
venous system have demonstrated that it can protect acutely
Ischxmle myaeardium. To evaluate the efficacy of coronary venous
retroinfusion compared with systemic mtraveoous administration
atrecotnhinant tissue-type plan inogen activator (ri 14 rings
were studied with a copper soil-induced Thrombus In the left
anterior descending coronary artery . The rt-PA (71,000 f lumes.
am aniNlsg) was administered continuously, either fntrave
nously (n = 8) or retragradely (a = 6), foe 30 min beginning
60 min after coronary occlusion . Thrombolysis was determined byt
repetitive coronary'
angiography.
AB dogs were killed 3 h after
termination ofri-PA infusion and infarct size was measured by the
triphenykk[razolium chloride staining technique
.
Complete thrambokysis occurred in five of the six dogs in the
retroinfuson groap and four of the eight dogs
in the systemic
Intnvessous iafnsion grmtp
. Partial lysis was achieved in lwu dogs
treated by intravenous infusion. Lysis did not occur in one dug
treated with relroinfusian and in two dogs treated with Imrave .
Various new therapeutic techniques for acute mvocard .a l
infarction have been developed in the past 2 decades .
Experimental (1-3) and more recently clinical 14-9) studies
have indicated that early and adequate restoration of coro-
nary blood flow after acute myocardial infarction can reduce
infarct size and improve myocardial function . large conm
domized clinical trials (10-131 have also demonstrated that
early coronary thrombolysis reduces the mortality rate in
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noun infuslw
. Time to thrunbolyris was 13 .4 t 2 .3 min in the
retroinfusion group Terms 27 .8 2 4.8 miss in the Intravenous
group (p < 0.001)
. Myocardial functional recovery In the Ischemic
zone mwmred by two-0larenskmal echecardlography 60 min after
reperfusion was significant only In the retrolnlhsion group (p <
0.051. Infarct slit expressed as a percent of the risk area (auto.
radiography) was slgaiheanlly smaller in the retecinfuakm group
(34.9 ± 11 .9%) than in the intravenous group (54.5 s 19.1%n ;
p < 0
.05) despite <15 min difference in average ischemk time
between the groups (73 .4 vs. 67.8 mint
.
It is speculated that
relrotnfuskn of rt-PA may prevent downstream embdization of
micrathrombl. No myocardial hemorrhages or damage to the
coronary venous system were observed .
It is concluded that coronary venom rdroinrusim of it-PA
provides more rapid dot Uxts and better functional recovery and
infarct sire reduction compared with systemic laeavemas admin.
islrativn .
(J Am Cell Cordial 1991 ;18:613-20)
patisolcs with acuue myocardial infarction . Streptokinase has
been commonly used in thrombolylic therapy administered
by an intracorenary (5 .6 .13) or intravenous (10-12) route ;
however, the results have not been fully satisfactory (14) .
More recently, new fibrin-specific thrombolytie agents such
as recombinant tissue-type plasminogen activator (tt-PA)
have been applied in clinical studies (15-19) .
Interventions by way of the coronary sinus have been
exrenslvcly studied (20) as an alternative route for delivery
of oxygenated blood and drugs into the jeopardized myocar-
dium during coronary artery
occlusion . Beneficial effects
of
synchronized retroperfusion (21-27) and retroinfusion (28-
31) of drugs on ischemic myocardium have been clearly
demonstrated in experimental studies . We (32) previously
showed that coronary venous retroinfusion of streptokinase
was associated with more rapid clot lysis compared with
systemic intravenous infusion in a model of acute coronary
artery occlusion.
The purpose of this study was to compare the efficacy of
retrograde administration of rt-PA into the great cardiac vein
with that of systemic infusion in the setting of a thrombus-
induced acute coronary artery occlusion, with respect to
m as.1mmusn.so
hid
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rapidity of lysis as well as early myocardial functional
recovery and ultimate infarct size .
Methods
Experimental preparation . Sixteen male or female mon-
grel dogs, weighing 20 to 35 kg, were premeditated with
morphine sulfate (I mgtkg body weight intramuscularly) and
anesthetized with sodium thiopental 125 mglkg intravenous-
ly) . After tracheal incubation, respiration was controlled
with a semiclosed circuit Harvard respirator . Respiration
volume and rate were adjusted to maintain arterial pH and
partial pressure of carbon dioxide (Pco 2) within the physio-
logic range (pH 7 .35 to 7 .45 ; Into, 35 to 45 mm Hg)
.
Anesthesia was maintained with a mixture of enflurane and
oxygen.
A 7F venous catheter was inserted into the inferior vena
cava far intravenous administration of saline solution and
tt-PA solution . Aortic and pigtail catheters were introduced
through the femoral artery into the ascending aorta and left
ventricle, respectively . and connected to a Statham P23Db
transducer
. In all dogs, a 5F
triple-lumen balloon-tipped
rctroinfusion catheter (Retroinfusion Systems) was intro-
duced into the coronary sinus through the left jugular vein
and advanced to the great earaiae veip. under fluoroscopic
guidance (Fig. i)- Two of these lumens opened at the end of
the catheter Lip and were used for pressure monitoring and
drug infusion . Another lumen opened into the balloon for
occlusion of the coronary sinus and compartmentalization of
the coronary veins to enhance drug delivery into the isch-
e is myocardium .
A copper coil-iesdacrd rhrmnhrre reefraique 1Pnr coed for
the coronary artery occlusion (33). After inserting a 7F
angiographic catheter from the left carotid artery into the
ostium of the left anterior descending coronary artery . a
straight guide wire 10.035 in . 10.069 cm) diameter) was
inserted 5 to 7 cm into the coronary artery through the
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Figure 1 . Scheme of the experimental preparation . A cap-
per coil it petitioned in the proximal left anterior descend-
iris caraway artery LAD) toiaduccthrombusformanan .A
5F
triple lumen balloon-tipped catheter is introduced into
the great cardiac vein tGCVI for regional coronary venous
occlusion . drug administration and coronary venous pres-
sure monitoring . C5 - coronary sinus: RA = right atrium-
angiographic catheter under fluoroscopic guidance . The
catheter was then withdrawn from the carotid artery. A 25
gauge copper wire coil (
10 to 12 mm in length, 2 to 3 mm in
outer diameter) was placed over the guide wire and ad-
vanced by the 7F catheter 2 to 3 cm into the proximal left
anterior descending artery
. After withdrawal of the intra-
coronary guide wire, the angiographic catheter was drawn
into the aortic root for later coronary angiography . Until
total heparinization was achieved, all catheter Lumens were
continuously flushed with saline solution at a low flow rate to
prevent clot occlusion.
Mantremenis . The electrocardiogram (ECG) and all
pressures were continuously monitored on an Electronics
for Medicine V .12 physiologic recorder. The left ventricular
short-skis view recorded with two-dimensional echocar-
diography (Advanced Technology Laboratories. model
MK300LXI was employed to measure myocardial systolic
function in the ischemic region, Short-axis views at the low
papillary muscle level were subdivided into eight equally
spaced segments, using a standardized fixed axis with an
internal referencing system (23) .
Percent
Sysrolfc fractionalarea change (VfFAC) was calcu-
fared bs the foflmving formula : SkFAC = l(EDA-ESA))
EDAI x 100. where FDA = end-diastolic area and fSA =
end-systolic area- These variables were calculated and ob-
tained with use of a computer-assisted system as previously
described (23) by an observer who did not know the angio-
graphic and palhelofic results . The ischemic segment was
defined as the segment that had the most depressed systolic
fractional area change during coronary Occlusion .
Experimental protocol. The ST segment elevation on the
ECG nod enteroseptal wall motion abnormality on the two,
dimensional
echocardiogram
were used Ibr confirmation of
ischemia in the distribution of the left anteriar descending
coronary artery . Coronary angiography was then performed
to confirm the coronary occlusion .
Before initiation of thrombolytic therapy . heparin
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(100IVtkg) was administered to prevent rethrom6osis an the
coil during and after thrombotytic therapy and subsequently
supplemented by 50 lU/kg intravenously every hour . The
dogs were then randomly assigned to one of the two treat-
ment groups.
Intravenous infnsiun group . Alter 60 min of occlusion,
human melanoma single chain rl-PA i24,t100 fluorescrncc
unitslkg [=0 .2 mglkgl [Bio-Response, inc .! dissolved into
240 ml of saline solutionl was co;ldnueusly infused over
30 min into the inferior vend cava .
Coronary sinus retroinfusion group . The same amount Of
rt-PA was continuously infused over 30 min through the
lumen of the retroinfusion catheter into the great cardiac
vein . If the mean great cardiac vein pressure was
<20 mm Hg, additional saline solution was reiroinfused
simultaneously to maintain the pressure at >20 mm Hg with
use of a Harvard peristaltic pump (model 500-12001
. When
the mean great cardiac vein pressure was >40 mm Hg or the
peak pressure was >60 mm Hg, the rate of infusion
of
additional saline suluGon was reduced or the balloon of the
retroinfusion catheter was deflated, or both, to reduce the
pressure . After recanalization, the catheter balloon was
deflated and additional infusion of saline solution was aban-
doned to prevent coronary venous damage by excessively
high coronary venous pressure .
To detect recanalizalion of the coronary artery, repetitive
angiography was performed at 5 min intervals (or immedi-
ately if significant reperfusion arrhyhmias (accelerated Win-
ventricular rhythm or frequent premature ventricular beatsi
occurred)
. To avoid manual transmission of hydrostatic
farce and high intracoronary arterial pressure during angiog-
raphy, the angiographic catheter tip was narrowed and never
wedged into the coronary artery . Reperfusion was defined
by the criteria described in the Thrombolysis in Myocardial
Infarction (TIMI( trial (9) . Administration of rt-PA was
continued for 30 min to complete the drug infusion protocol,
even if recanaliradon had already occurred . After recanati-
zation was confirmed, curenary agiugraphy was repeated at
5 and 10 min after reperfusien to confirm sustained potency .
Hemodynamic and rwo-dimenrianul echoeardio,rapflir
data were obtained heftlre coronary occlusion, after I h of
occlusion and then at 20 mirl and 1 . 2 and 3 h after rt-f .A
infusion . Three hours after completion of re-PA administra-
lion . the dogs were killed with an overdose of potassium
chloride.
Pathologic study- Autoradiegraphy was used to detect
the perfusion area with a bolus injection of 10 mCi of
technetium-99m-labeled albumin microspheres 13M Instant
Mierosphers, mean diameter 20 µml into the left ventricle
60 min after coronary occlusion 1341 . After induced death .
the heart was removed and the left ventricle was sliced into
5 to 7 mm thick transverse sections parallel to the atrioven-
tricular groove . These slices were incubated in triphenyliet-
razolium chloride solution for 30 min to define the area of
necrosis (represented by the unstained area) (351, Epicardial
and endocardial outlines as well as areas of necrosis were
MtYAZAKt ET AL.
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Table 1 . '1 h-botysis in
the Intravenous fn = 8) and Coronary
Venous Retroinfusion In m 6) Groups
Lysis Time
Thrunbolyve Ilulcome No . of Dogs (min)
tnlravenou, larm!- amup
ba-_.essIet unmAbAt5,~r n titan = 4; p-.1 = p
27
.8 a 4.8
U	ial rhromboly5k
ae,mlolushn Reap
Successful shranbolysis 5 lull = 3 : Carnal = 01 0 .4 *_ 2.3•
Unsuccessful .luombolysis 1
2
'p < 0 XJ versus line is intravenous infusion group. Values are mean
vulues u SD. full
-
full reperfusian : puelal - parlist reperfusion.
traced on transparent sheets . The slices were, then laid an an
X-ray film for 12 h . The exposed area by gamma-rays from
technetium-99m microspheres represented the perfusion
fnonischemic) area
. The exposed areas and outlines of cross
sections of the slices were traced on the same sheet ; there-
fore. ischemic areas were represented by the unexposed
areas on the sheet . The size of the ischemic and infarct areas
was quantified by planimetry and expressed as a percent of
the total cross-sectional area of all slices and as the ratio of
infarct to ischemic area . The coronary sinus and coronary
veins were also examined for damage from retroinfusion and
residual clots on the copper coil were examined .
Statistical analysis. The time of thrombolysis and infarct
size in the two groups were statistically analyzed by Stu-
dent's t test . Hemodynamic and two-dimensional echocar-
diographic data were analyzed by a repeated measure anal-
ysis of variance . When this analysis indicated intergroup
differences at one or more measurement times, the times
when differences occurred were further evaluated with
Scheie's I lest.
Results
Two dogs died before randomization and were excluded
from the study-
Thramholysis (Table 1). Intravenous infusion of n-PA
resulted in thrombolysis in six of the eight dogs . Full
rcperfusion (TIMI grade 3), however, occurred in only four
of these dogs . In the retroinfusion group, thrombolysis
uccurred in five of the six dogs and full reperfusion (TIMI
grade 3) occurred in all five dogs . Time to thrombolysis
(including dogs with partial lysis) was more rapid in the
retroinfusion group (13 .4 : 2 .3 mint than in the intravenous
infusion group (27.8
.
4 .8 min ; p < 0 .001) . There were no
clots at the site of the copper coil after induced death in any
dogs that showed full recanalization on arteriogaphy .
llemodynamics (Table 2). There was no statistically sig-
nificant difference in heart ride, mean aortic pressure,
left ventricular end-diastolic pressure or its first derivative
IdP)dtl between the two groups during the entire experimen-
tal period.
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Table 2. Hemmtynnml . Irnlu Vram the tntruvenum Infusion Group In '
61
and Coronary Venou . Retrmnfasion Group In - 41'
-Mg, without Ihrumbolysis are excluded . Dataiom one d ,,y in [hr coronary eenous revoinfusian group arc missingL dP+dl = first denvarivc of left ventricular
pressure . Values are mean - SD. LV = ten
-u-1-
LV EDP = Icft venuicular em4donlolic pressure .
infarctsize(Fig .2). Area at risk expressed as apercentof
left ventricle was approximately 357% in both groups . Infarct
size was significantly smaller in
the dogs in which rt-PA was
administered into the coronary vein (8,6 ± 6,373) than in
those receiving systemic intravenous infusion 1111.7 = 6.grh:
p < 0.051
. Infarct size expressed as a percent of the risk area
was also significantly smaller in the coronary
venous retruin-
Figure 2. Graphic representation of leftventrieulor(LV)ureaitrisk
and infarct si
cxprosscd is a portent of left ventrirk in the
intravenous infusion group Ripen ham
. n = 6t and the coronary
Venous retroinfusiun group (shaded ham. n = 51 Imcan values -
SDI
. Also shown a infarct art expressed as a
percent of the area at
risk . Infarct s signihcenuy smaller uft., coronary
no.,
retroinfusion of recombinant Tissue-type glasmlnogen activator than
n0rr systemic intravenous infusion . these data include only dogs in
which lysis wa, achieved . 'p < 0.115 versus intravcnnus infusion .
II I
f
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fusion group (34 .9 ± 11 .9%) than in the intravenous infusion
group (54 .5 -_ 19 .1fk : p < 0.05) .
Two •dimensional echocardtagraphy (Fig. 3)• After coro-
nary artery occlusion . regional myocardial function ex-
pressed as ischemic .one sys101ic fractional area change
Figure 3
. Regtooct ischemic myocardial funclion expressed as per-
cent systatie fetlonal area change (FACT in the inlraucnous
infusion group Ingot bars. n = 7 before repcsfusioni a = 6 after
reperfusion) and the coronary venous retroinfusiun group (shaded
ban. n = 5 before repedusion . n -
4 aaer reperfusion)_ Thrombotic
occlusion of the tell anterior descending coronary artery resulted in
akinesia in the ischemic ease . Isehemie tune function improved
with coronary venous retroinfusion of recombinant tissue-type
plasminoeen activator. but not by the systemic intravenous admin-
isttalion route
. Data than one dog in each group are missing
. 'p <
0.055 versos inlrannuus infusion .
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demonstrated severe dyskinesia in both groups. After reper-
fusion, ischemic
Zone function improved in dogs receiving
coronary venous
re-PA retroinfusion ; however, these values
remained at the hypokinetic level. Conversely, regional
ischemic zone function in dogs receiving systemic intrave-
nous infusion showed only transient minor recovery, return-
ing to dyskinesia after 2 h of rperfusion . The differences
between groups were statistically significant after 60 min of
reperfusion (p < 0.05) .
In the retroinfasion group . there was a strong inverse
correlation (r = -0 .89) between infarct size expressed as I
percent of areaat risk and ischemic zone function at 3 h after
reperfusion. In the intravenous infusion group. however .
there was no such correlation.
Relroinfusion and the coronary veins (Table 3) . Retroim
fusion was performed during continuous coronary venous
pressure monitoring . Coronary venous pressure was low
before retroinfusion and the peak pressure increased to 41
5 .8 mm fig during retroinfusion . Minimal pressure was
11 .6 2 4
.8 mm Hg and mean pressure reached 244
4.8 mm Hg. After completion of the retroinfusion . coronary
venous pressure returned to baseline values .
The coronary veins were fnipeeted after Me animals'
death. There was a small hemaloma around the coronary
sinus and slight endothelial erosion of the great cardiac vein
in one dog. There was no significant damage to the coronary
veins in my dogs in the rerronfusion group.
Discussion
Regional coronary venous administration o€ rl-PA re-
sulted in more rapid thrombolysis
. earlier recovery of re-
gional myocardial function and a greaser reduction in infarct
size compared with intravenous administration.
Previous studies on retruperrusion . Synchronized
perfusion with streptokinase for experimental coronary
thrombolysis was previously demonstrated by Meerbaum et
al
.
(32) . In that study, thrombolysis occurred more rapidly in
the retroperfusion group (51 ' 13 mint than in the systemic
intravenous infusion group 1132 ± 61 min] . even though the
MIYAZAKI ET AL .
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Tahk 3. Coronary Venous Pressure in the
Inuavenous Infusion Group and Coronary Venous
Retroinfusion Groups
thido After
Infusion Infusion
line Mgl
on
. Hg/
tOaa are presented ns mean values o
SID .
Darn
from one dog in each group are missing. Abbreviations as in
Table I .
doses of strptokinase were <20% of the amount currently
recommended for intravenous administration in patients
with acute myocardial infarction . We (36) previously showed
more rapid thrombolysis, earlier myocardial functional re-
covery and smaller infarct size using retrograde administra-
tion of streptokinase into the great cardiac vein without
synchronized retroperfusion of arterial blood in dogs . Be-
cause of differences in experimental design, it is difficult to
compare the time to thrombolysis between these two stud-
ies . However, from previous reports, it can be stated that
retrograde administration of streptokinase with or without
synchronized retroperfusion reduces the time to thromboly-
sis to <50h of that with systemic administration .
Gold et al . (57) reported that the time to thrombolysis
after intravenous administration of rt-PA was dose depen-
dent in an experimental study of coronary thrombolysis with
thrombin-induced thrombosis. Clinical studies (15,191 have
also shown dose-dependent thrombolysis after intravenous
administration of «-PA . Other studies (15,17) reported that
reperfusion occurred in approximately 700A of patients re-
ceiving 80 to 100 mg of rt-PA. whereas more recent studies
(18,191 have shown a recanalization rate of approximately
8011 with doses of 1 .25 mglkg or 150 mg and a linear trend
between the dose and the rate of success of thrombolysis
F&191. Therefore, rapid (hrombolysis and high recanaliza-
lion rtes may be dependent on high concentrations of the
drag in plasma and at the site of the thrombus .
Coronary venous retroinfusion of several pharmacologic
npvnrs has demonstrated that this technique is associated
with high myocardial drug concentrations in the ischemic
tissue (29 .38), similar to the concentrations achieved by
direct coronary artery infusion (39). Furthermore, studies of
coronary venous rctroperfusion of arterial blood (21) and
drug retroinfusion (29,38,39) have demonstrated transcapil-
lary delivery from the venous to the arterial side . Adminis-
tration of a thrambolytic agent into the coronary vein may
reach the arterial thrombus directly through capillaries and
from larger venoarlerial shunts as well as systemically .
Therefore, retroinfusion of a thromoolytic agent has the
peteatial to lyse the clot from both the proximal and the
liana-u:ra'urit=11
Maximum 9 u - 10 101 ' 1 2 6 .0 •. 3.5
Minimum • 3.1 5 .3 5 4.6 3 .3 - 3.1
Mean
50
17 7.0 r 3 .0 4 .7 a 3.2
aelromtuson group In - 51
Mammon 9.1
3 .8
41 .2=5$ 5.4=4
.1
Minimum I f n ; .5 11 .6=4,t 0.9t16
Mean 4 1 - , 9 14.1,54A i .0i29
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distal sides of the thrombus, which may explain the more
effective and more rapid thrombolysis observed in our study,
whereas thrombolytic agents administered systemically are
diluted m a large blood pool and can lyre the thrombus only
from the proximal arterial side .
tofaret size and myocardial function . This study also
shows smaller infarct size and better myocardial functional
recovery after retroinfusion than after systemic intravenous
infusion of rt-PA . The primary reason could be related to the
shorter period of isrhemia in the retroinfusion group (73 .4 ±
2.3 min} than in the systemic intravenous group (67 .8 --
4.8 min) . However, the average time difference from coro-
nary occlusion to thrombolysis between the two groups was
only about 15 min, which is probably too short to explain the
relatively large difference in infarct size (34 .9 ± 11 .97b vs.
54,5 ._ 19 .1%). This result suggests that retroinfusion may
lyre small thrombi or prevent microembolization in the
peripheral vascular bed distal to the occluded epicardial
coronary artery .
Even after short periods of itchemia, complete myocar.
dial functional recovery may be delayed for m24 h (40,41) . It
has been reported (421 that the pattern of reflow after
thrombolysis is unstable and intermittent . In the present
study, despite a relatively prolonged ischemic time, myocar-
dial functional recovery in the ischemic zone after reperfu-
sian was significantly faster in the retroinfusion compared
with the intravenous infusion group (p < 0 .05). Moreover,
this phenomenon was strongly related to the size of the
infarct. We believe that the lack of improvement in regional
function in the intravenous infusion group is related to the
larger infarcts in that group, even though we cannot rote out
the possible detrimental effect of thrombus dehri in the
mierocirculalion or the possibility of delayed functional
recovery had we extended the period of observation after
reperfusion . In the intravenous infusion group, even in the
dog with the smallest infarct (infarct sizeiarea at risk 24,5% .
time to lysis 27 min), there was severe dyskinesia in the
ischemic zone (area change -1 .4%) at 3 It of rperfusior
.
Therefore, tram these data, it is suggested that retroinfusion
of rt-PA enhances the actual or effective reperfusion in the
microvascular bed . resulting in a shorter period of severe
ischemia,
Coronary venous involvement . In the present study, cor-
onary venous pressure was continuously monitored during
the retrograde infusion because it has been shown
(21 .22,25,43) that high coronary venous pressure (mean
pressure >40 mm Hg or peak pressure >60 mm Hg) may
cause intramyocardial bleeding, edema er venuie damage . In
our study, mean coronary venous pressure was maintained
at approximately 20 mm Hg to achieve and enhance effective
retrograde drug delivery
. A previous study (44) also demon-
strated a close relation between coronary venous pressure
during retroinfusion and the resulting ischemic myocardial
perfusion. In oar study, all dogs in the retroinfusion group
were examined after death and there was no serious damage
in the great cardiac vein where the coronary venous occlu-
IACC Vol . Ir, No . 2
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sion was carried out. In a recent preliminary clinical study
(45), it was demonstrated that catheterization of the coro-
nary sinus can be easily performed in humans with a
pereulaneous approach and that retroperfusion is safe,
Study limitations . to the present study, although a coro-
nary sinus catheter was placed in both groups of dogs,
temporary coronary sinus occlusion was carried out only in
the coronary venous retroinfusion group . This is important
because some investigators (461 have previously reported
significant infarct size reduction with intermittent coronary
sinus occlusion, although this has not been confirmed by
others 147) . However, the coronary venous retroinfusion
group had only a single (and not intermittent) coronary sinus
occlusion, which to our knowledge has not been reported to
reduce infarct size. In fact, prolonged coronary sinus occlu-
sion is associated with a slight reduction in epicardial coro-
nary artery blood flow (4B). Intermittent coronary sinus
occlusion, however, should trot be confused with pressure-
controlled intermittent coronary sinus occlusion, which has
been more consistently associated with infarct size reduction
in experimental studies (49)-
Another limitation of our study was the lark of a bolus
infusion of rt-PA . In current clinical practice in patients with
acute myocardial infarction, rt-PA is usually given as a bolus
infusion (r0% of the total dose) followed by a 3 h continuous
infusion
. Although we did not give an initial bolus infusion,
the total dose of rt-PA was given in only 30 min in our study
as opposed to the 3 h administration in clinical practice.
Clinical implications . In clinical practice, thrombolysis is
an established and commonly used procedure for patients
with acute myocardial infarction, with reported (15-19)
moralization rates of 60% to 75% with intravenous admin-
istration of rt-PA. However, in the remaining 25% to 40% of
patients with unsuccessful thrombolytic rccanalization,
fail.
a m may be due to the delay in starting administration or the
less efficacious intravenous administration . or both . Recent
trials (50) employed larger intravenous doses than those used
earlier to enhance effective, recanaliaation rates_ Although
this practice increases the success rate, it also increases the
chance of severe accidental bleeding .
This study shows that coronary venous retroinfusion of
small doses of ri-PA provides more rapid thrombolysis and
more effective reperfusion than does systemic infusion
.
Early thrmbolysis was achieved using only 15% to 20%
of
the intravenous n-PA doses currently used in patients with
acute myocardial infarction . This effect nay be due to a
higher concentration of the drug around tile thrombus .
Earlier thrombolysis was associated with improved ischemic
zone myocardial function after reperfusion and infarct size
was also significantly reduced in dogs receiving rt-PA by
way of the coronary vein compared with that after systemic
infusion. This liffererce could not be explained on the basis
of a small difference in ischemic time between the two
groups . [t is therefore speculated that retroinfusion of rt-PA
may actually prevent embolization of microthrombi to the
microcirculation.
JACC V.I . 18, No . 2
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It is also possible to combine retroinfusion of throm-
bolytic agents with rctroinfusion of d
:uys
that have the
potential to reduce rcpeefusion injury or repelfusion arrhyth-
reias, or Both (J4-161 . Indeed . previous studies from our
laboratory 130 .31 .38) and others 128,51) comparing rctroin-
fusion with systemic drug infusion during acute coronary
ocClunion have demonstrated not only im
;reascd myocardial
drug concentration, but also enhanced efficacy of infarct-
reducing agents inlased through the coronary veins . partic-
ularly when these drugs are administered before reperfuslon
Thus, rctroinfusion of lhrombolytic agents can be used a6 an
alternative lot adjunct method Ira <_ y otemie ehrombolysis.
Investigation of the use of this technique in patients with
acute myocar'fial infarction may be justified .
We thank Myles I accost and Willis Curt . Pa forenoon technical assillance,
Ronald Anaga far typing sire reennsenpl and lunar Bloom for eddcrtal
antistance.
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